Nov 10, 2011 - determined by standard enzymaticmethods on a Hitachi Modular analyser (Roche. Diagnostics, Indianapolis,USA). ..... Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM; San Antonio Heart. Study. The metabolic syndrome as predictor
Science in medicine. 2764. The Journal of Clinical Investigation http://www.jci.org Volume 123 Number 7 July 2013. Introduction. The fuel-sensing enzyme .... AMPK and insulin resistance. Effects of exercise. As already noted, exercise increases whole
Physical Activity. (at least 20 minutes per day). Drink plenty of water. Thorne Modified MediTerranean Diet. The Thorne Modified. MediTerranean Diet goes a step further .... starting with a MediBolic smoothie is a great way ..... breaths. The more of
determine a metabolic syndrome diagnosis, and what nutritional and .... Making it Easy! The following website allows you to type in a food and receive its glycemic index and glycemic load. Use it as a general guide. Whenever possible ..... This is a
Jul 7, 2006 - The Journal of Clinical Investigation http://www.jci.org Volume 116 Number 7 .... of insulin resistance, but more information is needed to determine ..... the immune system mediate the effect of overnu- ... (EPIC)-Potsdam Study.
sampling, pacing, and flow measurements by thermodilution (36 ml saline per min for ... ria for satisfactory position of the coronary sinus catheter were an .... 0.080MVO2. (. 0.034 MVCO2 ). +. 4.18. Ã. = Table I. Clinical Characteristics of the Stu
Aug 4, 1980 - amined with the euglycemic insulin clamp technique ... METHODS. Subjects. 17 ambulatory volunteers with chronic (>3 yr) renal disease of diverse etiology were studied. There were 12 males and 5 females ranging in age from 23-57 yr (mean
Jun 6, 2008 - of MTP, apoB, and lipogenesis. Kamagate et al. demonstrate in CA-FoxO1 transgenic mice that increased VLDL-TG production and plasma apoB concentra- tions correlate with increases in the level of hepatic Mttp mRNA and MTP protein (7). Us
Methods: 123 subjects were examined; 65 of them suffered from metabolic syndrome (minimum of three indicators characterize metabolic syndrome) 30 healthy ... David Stejskal, MBA has completed his PhD from PalackÃ½ University and Post-doctoral studies
the insulin sensitivity and leanness/energy expenditure or whether these are regulated by independent signaling .... triglycerides, from which energy is called forth at times of need in the form of FFAs and glycerol. However, data ... sity for which
Jul 11, 1989 - MeanÂ±SE of samples drawn at 2.5- to 5-min intervals using a 20-min interval before indicated times. * MeanÂ±SE of samples drawn at indi- cated times. Â§ t test: P < 0.001 between groups. Synthase phosphatase activity was significantly
Jun 6, 1994 - Hereinafter, the forearm instrumented with the arterial catheter will be called infused forearm and the contralateral forearm control forearm. The fasting study consisted of three periods of 40-50 min each: basal, adenosine infusion (AD
Mar 3, 2007 - We rescued the embryonic lethality of global PPARÎ³ knockout by breeding Mox2-Cre (MORE) mice with floxed PPARÎ³ mice to inactivate PPARÎ³ in the embryo but not in trophoblasts and created a general- ized PPARÎ³ knockout mouse model, MO
to-hip ratio, indices of body fat distribution, was related to insulin sensitivity after adjustment for age, gender, ..... In the whole group, insulin sensitivity (as the Mffm) de- clined linearly with increasing BMI, at an ..... Manson, J., G. Coldi
Abstract. Inhibition of insulin receptor signaling by high glucose lev- els and by TNF- was recently observed in different cell sys- tems. The aim of the present study was to characterize the mechanism of TNF- âinduced insulin receptor inhibition a
ure shows, insulin levels and insulin secretion rates are clearly increased in insulin-resistant subjects. ... St. Louis, Missouri 63110-1093, USA. Phone: (314) 362-8060; Fax: (314) 362-8015; E-mail: [email protected] ... cell proliferation but
studies showed a three plus reaction for sugar and acetone in the urine. Albumin and many white cells were also ... headaches, some aching and burning of the legs and feet, nocturia one to three times, and considerable ..... possibly independent immu
5Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. While a potential causal .... in the IRâIRS-1/2âPI3Kâ. Akt pathway in case cohorts from the University of Pennsylvania .... Correspon
tests on human HF slices from 5 N cases with PMIs of 5â19 hours demonstrated that 0.1â100 nM insulin ...... 10 nM insulin on glucose uptake in HF slices and synaptosomes. The latter preparations were included to ...... receptors; translation of P
May 25, 2017 - Fatigue is the result of two main factors: â Dissipative losses of ATP through channels in the cell membrane, and. â Reallocation of cellular resources away from mitochondrial energy production (oxphos). â¢ This is the result of m
function of the pituitary-thyroid axis (1, 2, 3). In one study, vitamin Aâdeficient rats had significantly high- er serum T4 and T3 levels than were found in vitamin. Aâsufficient controls (3). Pituitary thyroid-stimulating hormone (TSH) content
course of illness, lower scores on the Global Assessment of. Functioning (GAF) scale and had received ... insulin resistance to have intermediate findings between those of patients who were euglycaemic and those .... response to treatment.15,16 We us
The facilitative transport of glucose across animal cell membranes is medi- ated by members of the Glut protein family (1). These 50- to 60-kDa glyco- proteins are ubiquitously expressed in mammalian tissues and are responsible for the uptake of suga
2The Joslin Diabetes Center and Harvard Medical School, Boston, Massachusetts 02215, USA. Address correspondence ... Thus, insulin resistance differentially affects the PI 3-kinase and MAP kinase signaling pathways, and insulin-stimulated .... Seven
Insulin Resistance and the Metabolic Syndrome Edward (Lev) Linkner, MD • Corene Humphreys, ND
DEFINING METABOLIC SYNDROME The terms “syndrome of insulin resistance (IR)” and “the metabolic syndrome” were coined in the 1980s by Gerald Reaven, MD, an endocrinologist at Stanford Medical School in California. Other names used to describe the condition include syndrome X, prediabetes, dysmetabolic syndrome, and cardiometabolic syndrome.1 Metabolic syndrome is associated with a constellation of risk factors for atherosclerosis and type 2 diabetes mellitus (DM) including2: • Elevated fasting glucose • Elevated triglycerides • Reduced high-density lipoprotein (HDL) cholesterol • Hypertension • Central obesity The presence of three or more of these risk factors defines the metabolic syndrome. Following a joint scientific statement by several major organizations, a set of defined cut off values were determined for all components, with the exception of waist circumference (Table 32.1).3 According to the National Cholesterol Education Program Adult Treatment Panel III, a waist circumference of more than 40 inches (101 cm) in men and more than 35 inches (89 cm) in women is a defining criteria for metabolic syndrome.4 These values apply to Western cultures only. For information regarding other ethnic groups, readers should refer to the 2010 article by Lear et al.5 that outlines existing and proposed waist circumference and waist-to-hip ratios. Additional abnormalities posited to define the metabolic syndrome include endothelial dysfunction, and procoagulant and proinflammatory states.6 IR is the most common clinical finding associated with metabolic syndrome and is thought by many investigators to represent the predominant mechanism underlying the pathogenesis of this condition. IR is defined as decreased cellular sensitivity to insulin and varies according to cell type, organ, and particular metabolic pathway.1 Research suggests that IR is associated with an inflammatory state and the activation of inflammatory pathways sustains IR and ultimately leads to the development of metabolic syndrome.7
PREVALENCE The incidence of metabolic syndrome has reached epidemic proportions, with nearly 35% of all U.S. adults and 50% of those aged 60 years and older estimated to
have metabolic syndrome in a 2015 report. Data from the National Health and Nutrition Examination Survey (NHANES) 2003 to 2012 reported a prevalence of metabolic syndrome of 33% (95% confidence interval [CI], 32.5% to 33.5%), with a significantly higher prevalence in women compared with men (35.6% vs 30.3% respectively; P < 0.001). When stratified according to ethnicity, the highest prevalence of metabolic syndrome is observed among Hispanics (35.4%; CI, 34.2% to 36.6%), followed by nonHispanic whites (33.4%; 95% CI, 32.6% to 34.2%) and blacks (32.7%; 95% CI, 31.5% to 33.9%). Overall, an increasing prevalence with advancing age has been reported for all ethnic groups. The prevalence of metabolic syndrome was reported as 18.3% among individuals aged 20 to 39 years and to be significantly higher at 46.7% among individuals aged 60 years or older.8 The increased prevalence of IR, metabolic syndrome, and type 2 DM is thought to be attributable to the global rise in the prevalence of obesity. Visceral fat is now considered to be involved in a number of metabolic, endocrine, and immune functions, all of which have been shown to increase risk of cardiovascular disorders.11 Metabolic syndrome is reportedly associated with a twofold increased risk of cardiovascular disease (CVD) and a four-fold increased risk of type 2 DM compared to individuals without the condition4 (Table 32.2).
PATHOPHYSIOLOGY The etiology of IR and the metabolic syndrome is multifactorial and encompasses genetics, nutrient deficiencies, and metabolic defects in addition to lifestyle and environmental factors. The pathophysiology of the metabolic syndrome involves a complex cascade of events that occur intracellularly. Insulin is a major hormone whose action is required for proper tissue development, growth, and maintenance of glucose homeostasis.12 Insulin also affects lipid metabolism by increasing hepatic and adipose lipid synthesis. IR is characterized by decreased responsiveness in the tissues to appropriate circulating levels of insulin and is considered the major contributor to the pathogenesis of metabolic syndrome (Fig. 32.1). Accordingly, IR in muscle tissues causes reduced glucose disposal from the bloodstream, and hepatic IR causes increased glucose production. Impairment of insulin secretion by pancreatic beta cells is a critical feature of the metabolic syndrome that leads to hyperglycemia due to defective insulin secretion and timing of the insulin response to glucose.13
Elevated blood pressure (drug treatment for hypertension is an alternate indicator) Elevated fasting glucose (drug treatment for diabetes mellitus is an alternate indicator)
Systolic 130 mm Hg or greater and/or diastolic 85 mm Hg 100 mg/dL or greater
Modified from Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 120(16):1640-1645, 2009 and Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 313(19):19731974, 2015. HDL, high density lipoprotein.
The key targets of insulin action are predominantly skeletal muscle (75%), followed by cardiac muscle, adipose tissue, and the liver. In the liver, insulin inhibits the production and release of glucose in healthy subjects by inhibiting gluconeogenesis and glycogenolysis. Defects in glucose transport or in the hexokinase II pathway may represent the principle mechanism underlying the inhibition of muscle glycogen synthesis. In vivo studies using nuclear magnetic resonance spectroscopy have demonstrated defects in muscle glycogen synthesis are caused by a defect in muscle glucose itself.14 The glucose transporter 4 (GLUT4) is the major carrier of glucose into the cell. Stimuli, such as insulin and exercise, promote GLUT4 activity by embedding it into the cell membrane. Peroxisome proliferator–activator receptors (PPARs) are nuclear hormone receptor transcription factors that cause target genes to be expressed and play essential roles as regulators of insulin action13 (Fig. 32.2). Previous definitions of IR generally considered the condition exclusively in terms of the negative effects on glucose metabolism. Such effects include hyperglycemia following a high carbohydrate meal and overstimulation of pancreatic beta cells to produce more insulin. Eventually, pancreatic beta cells become unable to produce sufficient insulin to maintain normal blood glucose levels. This inability of beta cells to produce sufficient insulin underlies the transition from IR to type 2 DM.15 It is important to emphasize that IR
Hemodynamic Changes • ↑ Sympathetic nervous system activity • ↑ Renal sodium retention • ↑ Blood pressure (50% of patients with hypertension have insulin resistance) Hemostatic Changes • ↑ Plasminogen activator inhibitor-1 • ↑ Fibrinogen Endothelial Dysfunction • ↑ Mononuclear cell adhesion • ↑ Plasma concentration of cellular adhesion molecules • ↑ Plasma concentration of asymmetric dimethyl arginine • ↓ Endothelial-dependent vasodilatation Reproductive • Polycystic ovarian syndrome • Low testosterone in men Data from Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8:272-283 and Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;106:286-288.
INSULIN RESISTANCE: Receptor and Postreceptor Defects
Insufficient glucose disposal
Increased glucose production
Liver Peripheral tissues Pancreas
Impaired insulin secretion FIG. 32.1 □ Sites of the Three Major Pathogenic Defects That Lead to Type 2 Diabetes Mellitus. Insulin resistance in muscle causes reduced glucose disposal from the bloodstream, and hepatic insulin resistance causes increased glucose production. Impairment of insulin secretion by pancreatic beta cells is a critical feature that leads to hyperglycemia when insulin secretion and the timing of the insulin response to glucose are defective.
occurs at the cellular level despite pancreatic beta cell dysfunction (Fig. 32.3). As further studies of the pathophysiology of IR have been reported, the traditional glucocentric view of IR has evolved to include the “lipocentric” concept. Scientists have discovered that abnormalities in fatty acid metabolism cause inappropriate build-up of fat in muscle tissue, the liver, and other organs. Lipotoxicity, associated with increased plasma free fatty acid levels, is a hallmark of IR. Subsequently, these lipids are associated with not only an abnormal accumulation but also increased fat oxidation with further damage to the cell.16,17 IR may involve the insulin receptor itself. The insulin receptor belongs to the receptor tyrosine kinase family which also includes insulin-like growth factor-1 receptor (IGF-1R) and the insulin receptor-related receptor (IRR). Therefore impairment of insulin-stimulated glucose uptake may also result from the upregulation of inhibitors of these signaling pathways. Furthermore, protein-tyrosine
phosphatases (PTPases) may also have a role as negative regulators of the insulin-signaling cascade. A combination of the downregulation and upregulation of certain receptors may be a key element of IR pathophysiology.13 Chronic, low-grade inflammation has also been posited to have a central pathogenic role in IR. Research has shown that proinflammatory cytokines and acute-phase reactants are associated with many features of the metabolic syndrome. These inflammatory cytokines promote IR through site-specific serine phosphorylation of insulin substrates.16 Therefore, IR, predominantly in skeletal muscle, manifests as a reduction in insulin-stimulated glycogen synthesis resulting from decreased glucose transport. Once this occurs, lipid accumulates in many cells, most importantly in the liver and pancreas, causing oxidative stress and deleterious changes to cellular metabolism. These multiple defects in insulin signaling have been posited to underlie downstream impaired glucose metabolism in
FIG. 32.3 □ Natural history of diabetes, depicting rising blood glucose levels with progressive beta cell dysfunction.
most tissues13,18 (Table 32.3). These pathways are summarized in Fig. 32.4. Impact of Environmental Toxins on Metabolic Syndrome and Type 2 Diabetes MellitusNew research points to the role of environmental toxins as etiological factors in the pathogenesis of IR and type 2 DM. The organic compound bisphenol A (BPA) has been found to have an association with IR and type 2 DM. BPA is used to make polycarbonate and epoxy resins and is primarily found in food and beverage containers. BPA has been used commercially since 1957, with more than 90% of U.S. residents estimated to have detectable levels in urine. Findings from the 2003–2008 NHANES report revealed an association between BPA and prediabetes, independent of traditional risk factors.19 Based on experimental studies, BPA appears to affect glucose metabolism through a number of pathways including insulin resistance, pancreatic beta cell dysfunction, adipogenesis, inflammation, and oxidative stress.19 Other pollutants, such as air pollution20 and traffic-related pollution,21 have also been implicated in IR and increased risk of mortality attributable to type 2 DM. Persistent organic pollutants (POPSs) may also play a role in the pathogenesis of the metabolic syndrome and type 2 DM. POPs are a class of compounds characterized by low water and high lipid solubility, an ability to persist in the environment, and a cause of biomagnification in the food chain. Pesticides, solvents, and foods from animals, such as seafood, are the main sources of POPs. Because POPs are lipophilic, these substances are highly resistant to degradation and have an estimated half-life of 7 to 10 years.45 Some of the most common POPs found in humans include dioxins, polychlorinated biphenyls, dichlorodiphenyldichloroethylene, transnonachlor, hexachlorobenzene, and hexachlorocyclohexanes.46 In the 1999–2002 NHANES report, higher concentrations of POPs (mainly pesticides and herbicides) were associated with an increased prevalence of type 2 DM. Subjects in the highest category (more than the 90th percentile) of exposure, as compared with the lowest category (less than
ATHEROSCLEROSIS FIG. 32.4 □ Summary of Insulin Resistance and Its Effects. DM, diabetes mellitus; Na+, sodium.
the 25th percentile), had a 38-fold (P < 0.001) increased prevalence of type 2 DM. Obesity was not found to be a risk factor for type 2 DM in individuals with undetectable levels of persistent organic pollutants.47 A year later, the same research group reported a positive correlation between POPs (in particular organochlorine pesticides) and the metabolic syndrome.48 According to a Lancet
editorial, the findings from the study by Lee et al. might imply that “virtually all of the risk of diabetes conferred by obesity is attributable to persistent organic pollutants, and that obesity is only a vehicle for such chemicals.”46 In a 2013 review of the epidemiological evidence of an association between POPs and diabetes, Magliano et al.45 concluded that there is an independent relationship between POPs exposure and diabetes in the general population as well as occupationally exposed and high-risk populations. Inorganic arsenic is another environmental toxin that appears to be associated with the metabolic syndrome and type 2 DM. The primary sources of inorganic arsenic are contaminated drinking water due to naturally occurring arsenic in rocks and soils, and food.49 Organic arsenic is predominately derived from the ingestion of fish and shellfish, and is considered nontoxic as it is excreted unchanged in the urine. Results from the 2003–2004 NHANES cross-sectional study revealed a positive association between increasing levels of total urinary arsenic and type 2 DM. Subjects with type 2 DM had 26% higher total arsenic levels than subjects without DM. In the fully adjusted model comparing the 80th and 20th percentiles of total urine arsenic (16.5 vs 3.0 g/L), the odds ratio for type 2 DM was 3.58.50 No association was observed between organic arsenic and type 2 DM. The investigators suggested that 8% of public water systems in the United States exceed the U.S. Environmental Protection Agency’s standard of 10 mcg/L for drinking water.50 Wang et al.51 also found an increased prevalence of metabolic syndrome in subjects with elevated hair arsenic levels. After adjustment for confounding variables, subjects with hair arsenic in the 2nd tertile (0.034 mcg/g) had a statistically significant increased risk of metabolic syndrome (odds ratio, 2.54; 95% CI, 1.20 to 5.39; P < 0.015). Inorganic arsenic is thought to increase the risk of type 2 DM by stimulating increased expression and secretion of high sensitivity C-reactive protein (hs-CRP), which in turn activates nuclear factor kappa-beta via the Rhokinase pathway.52
Metabolic syndrome is primarily an environmental phenotypic disorder (92%) rather than a genotypic disorder (8%).
Nonalcoholic Fatty Liver Disease Nonalcoholic fatty liver disease (NAFLD) has been defined as the accumulation of fat in the liver (hepatic accumulation of greater than 5% of liver weight confirmed by magnetic resonance spectroscopy or liver biopsy) in the absence of other specific causes of liver infiltration, such as recent or significant alcohol ingestion, hepatic viral infections, or other causes of liver disease.53,54 NAFLD is now the most common chronic liver disease worldwide, affecting both adults and children with an estimated prevalence of 20% to 35% in the general population.55 Traditionally NAFLD has been viewed as a histological continuum from pure fatty liver (steatosis) through nonalcoholic steatohepatitis (NASH) to liver fibrosis, potentially leading to liver cirrhosis associated
with increased risk of hepatocellular carcinoma.53 The histological progression of NAFLD begins with micro– macro vesicular steatosis, which primarily affects the perivenular regions, and may extend to panacinar distribution. The diagnosis of NASH is informed by the presence of fatty infiltration accompanied by inflammation associated with one of three additional features on liver histology: hepatocyte ballooning; Mallory hyaline; or fibrosis.54,56 IR is considered the initial injury to the liver, which leads to increased uptake and synthesis of free fatty acids and impaired inhibition of adipose tissue lipolysis with resultant steatosis. Following initial fatty infiltration, the liver becomes increasingly vulnerable to multiple hits including gut-derived bacterial endotoxins, cytokine and adipokine imbalance, mitochondrial dysfunction, oxidative stress, lipid peroxidation, Kupffer cell activation, and hepatic stellate cell activation.58 These multiple hits are proposed to stimulate hepatocyte injury and the progression from steatosis to NASH and ultimately fibrosis and cirrhosis (Fig. 32.5).59 Single nucleotide polymorphisms (SNPs) appear to be associated with NASH but not simple steatosis. NASH confers an increased risk of cirrhosis and secondary malignancy, partly attributable to genetic predisposition. Immunological events are believed to play a role in the development and progression of NASH, and to be associated with hepatic apoptosis and fibrogenic responses. Additionally, impaired regeneration of hepatic progenitor cells appears to be a unifying pathophysiological pathway for NASH, with resultant dysregulated adipokine production and fibrosis.53 In recognizing simple steatosis and NASH as two discrete entities with different etiologies, clinicians can identify and more closely monitor patients at greatest risk of liver fibrosis and cirrhosis, and individualize therapeutic interventions.
The Interrelationship Between Nonalcoholic Fatty Liver Disease and IR NAFLD is considered the hepatic manifestation of metabolic syndrome, as IR is currently considered the fundamental underlying pathogenetic mechanism underlying the development of hepatic steatosis. Additionally, all key components of metabolic syndrome (abdominal obesity, impaired fasting glucose, dyslipidemia, and elevated blood pressure) have been identified as major risk factors for the development and progression of NAFLD.55 Based on epidemiological studies, cardiovascular disease is the leading cause of death in NAFLD patients, followed by malignancy and liver disease, respectively. These findings imply NAFLD is a strong risk factor for cardiovascular disease and cardiovascular-related mortality.61,62 The prevalence of NAFLD is estimated to be 50% to 100% in obese and overweight patients, and 30% to 50% in patients with metabolic syndrome.55 NAFLD combined with metabolic syndrome is reportedly correlated with greater severity of liver disease and increased likelihood of NASH, independent of age, sex, and body weight. Given the high prevalence of NAFLD, it has
32 Insulin Resistance and the Metabolic Syndrome Altered VLDL secretion
Steatosis >5% liver fat
Inadequate β oxidation
Systemic factors Genetic risks
Lowered ATP and production of ROS
Fat droplet and ER injury
Accumulation of fat droplet; ER and cytoskeleton injury
ER stress response
Necrosis and neuroapoptosis Ductal reaction
IL-6 IL-8 NF-κB JNK
Inflammation Stellate cell activation
Mitochondrial permeability and cytochrome leak
Systemic factors • Gut endotoxin • Adipokines • Adrenergic tone
Fibrosis/cirrhosis FIG. 32.5 □ Illustration of Molecular Events Involved in the Pathogenesis of Nonalcoholic Fatty Liver Disease. ATP, adenosine triphosphate; ER, endoplasmic reticulum; IL, interleukin; JNK, c-Jun-N-terminal kinase; NF-κβ, nuclear factor kappa beta, a B cell–specific transcription factor; ROS, reactive oxygen species. (Reprinted with permission from Xiao J, Fai So K, Liong EC, Tipoe GL. Recent advances in the herbal treatment of non-alcoholic fatty liver disease. J Tradit Complement Med. 2013;3(2):88-94.)
been proposed that NAFLD be incorporated into diagnostic criteria for the metabolic syndrome.55 In the hepatic IR state, fatty infiltration is characterized by an increase in free fatty acids (FFAs) from sources including diet, adipose tissue, and de novo lipogenesis. Persistently increased glucose and hyperinsulinemia stimulate de novo lipogenesis by upregulating a number of transcription factors, which increase the activity of lipogenic enzymes. Fructose and high-fructose corn syrup have been identified as sugars that stimulate lipogenesis more profoundly that glucose. Ordinarily, FFAs are transported to the mitochondria for beta-oxidation or undergo esterification for excretion in VLDL or storage as fat droplets. IR-induced upregulation of FFAs causes direct hepatotoxicity via a number of intracellular responses. Excess FFAs activate the endoplasmic reticulum stress response, cause leakage during mitochondrial beta-oxidation, and lipid peroxidation in mitochondria (primarily), microsomes, and peroxisomes leading to reduced intracellular antioxidant capacity and increased oxidative stress. These mechanisms promote cellular apoptosis, a self-protective cellular response and key pathogenic event in NAFLD. Prolonged and increased levels of reactive oxygen species generated from mitochondrial dysfunction ultimately lead to steatosis and hepatic fibrosis.58
DIAGNOSIS Metabolic syndrome can be diagnosed using the criteria described in Table 32.1. Outside a research laboratory, standard of practice for the diagnosis of the metabolic syndrome is to conduct a 2-hour glucose and insulin tolerance test (GITT), which can easily be ordered through any outpatient laboratory. The protocol is as follows: (1) 2 days of carbohydrate loading, (2) blood sampling for fasting glucose and insulin measurements, and (3) consumption of a 75-g glucose drink. Thereafter, blood specimens for glucose and insulin measurements are obtained (but not always necessarily) at half-hour intervals for the first hour, followed by a final specimen 2 hours later. In the majority of patients, fasting and 2-hour measurements are sufficient. Essentially, this protocol is the standard glucose tolerance test (GTT) with concomitant insulin testing. A caveat of this approach is that clinicians should ensure the laboratory used is familiar with diagnostic procedures involving insulin, which is a very unstable hormone in vitro. False-negative diagnoses are possible if only a fasting insulin specimen is obtained. Regular drawing of blood specimens for the measurement of insulin is required to maintain test functionality. Clinician are required to understand the effect of insulin on managing blood glucose levels following glucose
consumption. Baseline fasting insulin levels should normally be less than 15 microunits/mL and less than 30 microunits/mL at 2 hours following consumption of a 75-g glucose load. Although the 2-hour GITT is considered the most accurate and functional test, other methods for the diagnosis of the metabolic syndrome include the following: • Triglyceride-to-HDL cholesterol ratio (TG:HDLC)—a healthy ratio is less than 2. • Glycosylated hemoglobin (HbA1c): values for patients with IR are between 5.7 and 6.4 as per the 2010 American Diabetes Association guidelines.63 • Fasting insulin: When assessed in isolation, normal values should be less than 15 microunits/mL (140 pmol/L); however, a normal fasting insulin result does not rule out IR. Reference ranges are laboratory specific, so clinicians must check with the clinical laboratories for specific values. In addition, what is “normal” and what is “healthy” can be vastly different. Other markers of importance include elevated hsCRP, uric acid, small dense low-density cholesterol (sd LDL-C), and inflammatory markers such as IL-6 and IL-8, TNF-alpha, PAF-1, and adiponectin. Because NAFLD is hypothesized to represent the hepatic manifestation of IR, the measurement of gamma-glutamyl transpeptidase (GGT) levels should also be considered as this transaminase enzyme is the most sensitive in detecting liver toxicity. For the majority of clinicians, the 2-hour GITT is the most valuable in terms of diagnosis and patient education, particularly for normal-weight individuals suspected to have metabolic syndrome and women with polycystic ovarian syndrome.
INTEGRATIVE THERAPY Lifestyle intervention offers the greatest promise for the prevention and management of the metabolic syndrome.
Lifestyle Factors Although the pathogenesis of IR is multifactorial, lifestyle factors are known to have a profound effect on blood glucose homeostasis. According to statistics reported in 2009, at least 92% of type 2 DM cases are related to lifestyle choices.64 Lack of exercise, central adiposity, and a diet high in refined carbohydrates and saturated fats and low in fiber represent key lifestyle characteristics associated with IR and type 2 DM. Knowler et al.,65 researchers in the Diabetes Prevention Program, compared lifestyle modification with diet and medication in more than 3000 patients with prediabetes. The investigators assigned patients to three groups who received one of the following: (1) metformin 850 mg twice daily, (2) a lifestyle modification program with goals of at least 7% weight loss, or (3) placebo. After 3 years of followup, the metformin group contained 31% fewer diabetics, and the lifestyle modification group contained 58% fewer subjects with diabetes compared with the placebo group.
Exercise, weight loss, and a healthy diet are key lifestyle interventions for reducing IR and the risk of developing type 2 DM.7 Exercise Regular exercise is a vital component of a holistic medical treatment plan and has been shown to reduce the incidence of IR by half.66 Patients with IR and metabolic syndrome are recommended to partake in 30 to 60 minutes of moderate-intensity aerobic workouts (e.g., brisk walking) at least five times per week. Resistance training should also be encouraged up to twice weekly.7 Exercise offers a number of physiological and mental/emotional benefits. One physiological benefit is that exercise enhances GLUT4 transporter activity, which in turn facilitates glucose entry into cells while bypassing the need for insulin.67 This effect has been demonstrated both in healthy individuals and those with IR or T2DM. Preliminary research also suggests that exercise has utility in improving the inflammatory state associated with IR by reducing levels of proinflammatory chemokines.68 Yoga is another modality proven to help reduce oxidative stress in patients with type 2 DM. Yoga combined with standard care reportedly improves glycemic control and reduces body mass index.69 Other benefits of regular workouts include increased lean muscle mass and reduced body fat (see Chapter 91). Weight Management Excessive food consumption, particularly dietary fat and foods with a high glycemic index, is a key contributor to the pathogenesis of IR and metabolic syndrome.2 Although the majority of patients with IR are overweight, a small subgroup of patients has a normal body mass index. These patients are termed metabolically obese, normal-weight individuals and share the same risks of developing type 2 DM and cardiovascular disease due to increased visceral fat.70 Increased visceral fat is associated with increased release of free fatty acids and initiates a self-perpetuating cycle leading to the development of increased IR. Affected patients are said to be “bathed in cortisol” and have the appearance of Cushing syndrome. As previously mentioned, this type of fat affects other organs by causing dysfunction and increasing inflammation. Adipose cells are not, as previously believed, passive depots for energy but are rather hormonally active by secreting adipokines. Adipose cells have also been shown to secrete TNF-alpha, adiponectin, resistin, leptin, and other inflammatory mediators, all of which are involved in the promotion and exacerbation of IR. Hu et al.71 reported sedentary behaviors (particularly watching television) are associated with significantly elevated risks of visceral adiposity, irrespective of exercise levels. Studies have reported that even small percentages of weight loss (6 to 10%) can significantly improve IR and reduce the risk of developing type 2 DM by 58%.65,72 Weight reduction (coupled with exercise) has also been shown to improve histological disease activity in patients with NAFLD.58
32 Insulin Resistance and the Metabolic Syndrome As little as 10% weight loss can reverse fatty infiltration of the liver.
The speed of chewing has also been shown to have an impact on diabetes risk. Fast eating is reported associated with a more than two-fold increased risk of type 2 DM compared with slower eating.73 Eating quickly has also been positively associated with body mass index, increased body weight, and weight gain based in a nationwide survey of middle-aged women.74
Nutrition For patients with insulin resistance, the focus should be on diets rich in whole grains rather than refined grains, fish and white meat instead of red meat, and plenty of fruits and vegetables along with nuts, legumes, and soy. In 2002, researchers from the Harvard School of Public Health published a set of nutritional guidelines known as the Alternative Healthy Eating Index (AHEI) with an emphasis on the foods listed previously. Results from the Whitehall II Prospective Cohort Study showed that adherence to the AHEI in a middle-aged population was associated with a reversal of the metabolic syndrome after 5 years (odds ratio 1.88; 95% CI, 1.04 to 3.41). This effect was more pronounced in subjects with central obesity and elevated serum triglycerides.75
The Mediterranean and low glycemic index/load diets are considered the most effective nutritional regimens for the treatment of metabolic syndrome, insulin resistance, and NAFLD.
Mediterranean Diet Much has been written about the Mediterranean diet, which is rich in vegetables, legumes, soy products, fish, and essential fatty acids. This type of diet is also low in refined carbohydrates and “junk foods,” as well as in red meat, which is rich in saturated fats.55 The beneficial effects associated with adherence to the Mediterranean diet relate to the nutrient-dense properties of the foods (i.e., vitamins, minerals, phytochemicals, and fiber).55 In a randomized trial, Esposito et al.76 compared a Mediterranean diet with a standard diet in 180 patients with metabolic syndrome. After 2 years, only 40 out of 90 subjects on the Mediterranean diet still had features of metabolic syndrome compared with 78 out of 90 participants in the standard diet group. A recent paper by Salas-Salvadó et al.77 also demonstrated a significant reduction in the incidence of type 2 DM with adherence to a Mediterranean diet. In this trial, nondiabetic subjects aged 55 to 80 years old were randomly assigned to either a low fat diet (control group), a Mediterranean diet supplemented with 1 L/week of free virgin olive oil, or a Mediterranean diet supplemented with 30 g/day of nuts. All diets were ad libitum. After 4 years, the incidence of type 2 DM was 18% in the control group, 10% in the Mediterranean plus olive oil group, and 11%
in the Mediterranean plus nuts group. When pooling the Mediterranean diet groups, there was a 52% reduction in the incidence of type 2 DM when compared with the control group. Of particular interest was the fact that the reduced incidence of type 2 DM occurred in the absence of any significant alterations in body weight or physical activity. Adherence to the Mediterranean diet has also been associated with reduced risk of metabolic syndrome in NAFLD patients55 (see Chapter 88). Low-Glycemic Index Foods The glycemic-index is a system for classifying carbohydrate-containing foods based on glycemic response. Carbohydrates range from simple sugars to starches and can all be converted to glucose. The rate at which conversion occurs is determined by saccharide chain length, with longer chains constituting complex carbohydrates. The glycemic index value for carbohydrates can vary by more than fivefold, with starchy foods having a higher glycemic index than nonstarchy foods such as fruits, vegetables, and legumes. Diets that favor high-glycemic index foods are associated with increased 24-hour glucose and insulin levels in addition to higher levels of C-peptide and glycosylated hemoglobin. These effects have been demonstrated in both nondiabetic and diabetic individuals.78 Research has shown that a combination of exercise and a low-glycemic index diet in obese subjects with prediabetes not only improves postprandial hyperinsulinemia but also reduces pancreatic beta cell stress. Conversely, exercise in combination with a high-glycemic index diet impairs beta and intestinal K cell function despite a similar reduction in weight loss. These findings emphasize the importance of diets rich in low-glycemic index foods that support beta cell preservation, a key factor in the prevention of type 2 DM79 (see Chapter 87). Fiber Dietary fiber, either from whole foods or dietary supplements, is a vital component of the treatment plan for IR and metabolic syndrome. Fiber helps reduce blood pressure as well as total and LDL cholesterol levels, and it modifies inflammatory markers. When taken with meals, soluble fibers, such as psyllium, have been shown to improve postprandial glycemic index and increase insulin sensitivity. Psyllium appears to work by reducing glucose absorption from the intestine and increasing GLUT-4 protein expression in muscles. Regular consumption of dietary fiber also promotes weight reduction by enhancing satiety. Oats and barley are other examples of soluble fiber that have U.S. Food and Drug Administration (FDA)-approved health claims for reducing the risk of heart disease.4 Cooking Techniques Cooking methods can also have an impact on biochemical markers associated with IR and metabolic syndrome. High-heat-treated foods typically found in the Western diet generate harmful compounds known as Maillard
reaction products. These compounds have been found to reduce insulin sensitivity and increase plasma cholesterol and triglycerides.80 Mild cooking techniques such as steaming, poaching, and stewing are recommended instead of roasting, barbecuing, broiling, or frying. Therapeutic Foods Blueberries are rich in phenolic compounds and anthocyanins and have been demonstrated to have certain health benefits, including improved cognition and reduced cardiovascular and cancer risk. Preliminary research suggests blueberries may also exhibit antidiabetic effects. In a double-blind, placebo-controlled randomized trial, consuming the equivalent of two cups of fresh blueberries a day improved IR in nondiabetic and obese insulin-resistant individuals.81 Consuming this quantity of blueberries has also been shown to reduce blood pressure, oxidized LDL cholesterol, and lipid peroxidation in patients with metabolic syndrome.82 Apple cider vinegar (20 g diluted in 40 g of water) has been shown to reduce postprandial fluxes in glucose and insulin following a carbohydrate-rich meal. Acetic acid in vinegar acts similarly to medications such as acarbose and metformin by suppressing disaccharidase activity and increasing glucose-6-phosphate concentrations in skeletal muscle.83 Other forms of vinegar, such as white vinegar in a vinaigrette sauce, can also be used to lower postprandial glucose (20 to 28 g white vinegar mixed with 8 g olive oil).84,85 Another first step would be to promote the patient’s own acid production by stopping unnecessary chronic usage of antacid medications if possible. Foods and Substances to Avoid or Consume in Moderation Table 32.4 provides a list of foods and substances that should be avoided, given their direct or indirect role in affecting glucose and insulin metabolism. Research has shown that low to moderate alcohol consumption (one to two standard drinks per day) increases insulin sensitivity and reduces insulin concentrations in nondiabetic postmenopausal women. However, regular consumption in this cohort also increased levels of the steroidogenic hormones DHEA-S and estrone sulfate, which are possible risk factors for breast cancer.86 Alcohol appears to have a U-shaped relationship with metabolic syndrome, with nondrinkers and heavy drinkers having a similar risk profile. This curious finding may be attributable to increased levels of HDL cholesterol observed in heavy drinkers.87 As the potential risks may outweigh the benefits, teetotalers should not be encouraged to start drinking to reduce their risk of developing type 2 DM. Smoking should be avoided as it is a known health hazard and shown to be associated with an increased risk for type 2 DM.88
Mind Body Stress Management Relaxation techniques are valuable in the treatment of IR because they promote stabilization of adrenal gland
TABLE 32.4 Foods to Avoid in Patients With Insulin Resistance and the Metabolic Syndrome Food/Substance
Refined Starchy Foods
Instant rice, potatoes, white breads, pasta, cereals such as Rice Krispies and corn flakes, corn chips, and canned foods have a high glycemic index and are known to impair glucose metabolism and increase insulin secretion.78
These foods are calorie rich, given their high sugar and fat content, and contribute to weight gain, insulin resistance, and hyperlipidemia.2
Sugar Sweetened Beverages
Soft drinks, fruit drinks, iced tea, and energy and vitamin water drinks are often rich in fructose corn syrup and are associated with weight gain and an increased risk of IR and type 2 DM.89 Consuming one to two drinks/ day is associated with a 26% increased risk of developing type 2 DM.90 Artificial sweeteners, such as aspartame, saccharin, and sucralose, are associated with obesity and a twofold increased risk of type 2 DM.91
DM, diabetes mellitus.
function. Stress management lowers both cortisol levels and blood pressure, increases DHEA, improves immunity, and reduces anxiety and depression. Patients are therefore less likely to abuse their bodies and tend to feel better about themselves following the use of relaxation techniques. A prescription with an individualized approach involving meditation, relaxation techniques, prayer, visualization, and other stress-reducing modalities is indicated in patients with IR or type 2 DM.92
Stress management and exercise are key components of therapies for IR and type 2 DM.
Depression The results of a 2009 study by Takeuchi et al.93 indicate the metabolic syndrome may be a predictive factor for the development of depression but not anxiety. Multivariate analysis indicated that an increase in waist circumference was the main factor influencing the relationship between metabolic syndrome and new-onset depression. Skilton et al.35 also found a positive association between depression (versus anxiety) and metabolic syndrome. In light of their research, the investigators posited screening for depression in patients with the metabolic syndrome.
Supplements Numerous nutritional supplements have demonstrated a beneficial effect on glucose and insulin metabolism. Patients with IR and metabolic syndrome should
include a multivitamin as a core component of their health regime. Certain nutrients, including antioxidants, may be required in therapeutic doses to ensure a physiological effect in the management of IR and metabolic syndrome.94-96 Supplementation with the following nutraceuticals should be guided by overall health and dietary habits along with laboratory parameters and current IR status. Vitamin B6 A deficiency in vitamin B6 is associated with a decrease in several important enzymes that contribute to gluconeogenesis (the generation of glucose from nonsugar substrates).97 In patients taking metformin for polycystic ovarian syndrome, vitamin B6 and folate have been shown to counteract increases in homocysteine levels.98
Dosage The recommended dose of vitamin B6 is 50 mg to 100 mg/ day.99 Precautions None have been reported at the recommended dose. Higher doses (>150 mg) may cause reversible neuropathy.
Folic Acid The combination of IR and elevated plasma homocysteine levels is associated with cardiovascular risk. Research has shown that patients with this combination of risk factors also have altered or reduced folate levels, which are thought to lead to the progression of hypertension.100 High dose supplementation with folic acid has been shown to protect against microvascular complications associated with metabolic syndrome101 and improve metabolic profiles in women with polycystic ovarian syndrome.102 Patients heterozygous or homozygous for the methylenetetrahydrofolate reductase single nucleotide polymorphism (MTHFR C677T) may benefit from supplementation with L-5-Methyltetrahydrofolate rather than folic acid.
Dosage The recommended dose of folate is 500 mcg to 5 mg/day.99-102 Precautions None have been reported. The administration of high doses of folic acid to patients with a concomitant vitamin B12 deficiency may correct megaloblastic anemia but increase the risk of irreversible neurological damage.103
Vitamin B12 Research has demonstrated a negative correlation between B12 status and body mass index.104 In patients with metabolic syndrome, the administration of folate
and vitamin B12 reportedly decreases IR and improves endothelial function. Homocysteine levels have also been shown to improve with folate and vitamin B12, affirming the beneficial effect of these treatments on cardiovascular disease risk factors.105 Because metformin has been shown to impair vitamin B12 status, practitioners should assess and monitor B12 levels in patients receiving metformin.106
Dosage The recommended dose of vitamin B12 is 500 mcg/day.107 Precautions None have been reported at the recommended dose.
Vitamin C Individuals with metabolic syndrome have been found to have significantly lower levels of vitamin C compared to healthy individuals.108,109 A deficiency of vitamin C is thought to be associated with a greater resistance to fat mass loss.110 High doses of vitamin C have also been found to reverse the adverse effects of free fatty acids on vascular function.111,112
Dosage The recommended dose of vitamin C is 1000 to 2000 mg/ day.113 Precautions Take with food to reduce the risk of diarrhea.
Vitamin D Supplemental (and dietary) vitamin D has been shown to reduce the development of metabolic syndrome.114 In a study of young adults, an inverse relationship between blood glucose, IR, and serum 25-hydroxy (OH) vitamin D was demonstrated.115 Other research has confirmed that serum 25(OH) D levels positively correlate with insulin sensitivity.116,117 Ford et al.118 also reported significant inverse relationships between serum vitamin D levels and abdominal obesity, elevated triglycerides, and hyperglycemia. Visceral fat reduces the absorption of vitamin D from the skin.
Dosage The recommended dose of vitamin D is 300 to 2000 IU/ day.119,120 Dosing may also be guided by the season of the year and serum 25(OH) D levels (the preferred range is 30 to 60 ng/mL or 75 to 150 nmol/L).121 Precautions Monitor serum calcium levels in patients taking thiazide diuretics and vitamin D supplements, as this combination may cause hypercalcemia.122
Vitamin E Vitamin E supplementation has demonstrated hepatoprotective effects in patients diagnosed with NAFLD (including those with NASH when accompanied with pharmacological medications).58,123
Dosage The recommended dose is 400 IU per day (or 200 IU twice daily) of alpha tocopherol or 400 mg of mixed tocotrienols.123-125 Precautions Exercise caution in patients taking anticoagulants, as chronic high dosing may affect blood clotting and induce symptoms of muscular weakness and fatigue (reported at doses of 720 mg alpha tocopherol per day).126
are associated with increased insulin sensitivity and a reduced risk of developing metabolic syndrome.135-137 Conversely, low dietary intake of magnesium is associated with an increased risk of developing IR and type 2 DM.138,139
Dosage A dose of 100 mg/day is recommended to reduce the risk of developing type 2 DM.140 A dose of 382 mg/day is required to improve metabolic profiles and blood pressure.134,141 Dosing can also be guided by assessing red blood cell magnesium levels. Precautions High-dose magnesium may cause gastric irritation and diarrhea.142
Zinc Biotin High-dose biotin is considered an important vitamin for preventing and treating IR and obesity.127 When given in quantities 10 times greater than the physiological range, biotin directly activates an enzyme that mimics the action of nitric oxide. Biotin has also been shown to improve glycemic control by reducing excessive hepatic glucose output.128
Dosage The recommended dose of biotin is 3 mg three times a day.127 Precautions None have been reported.
Recent research has reported an inverse relationship between serum zinc concentrations and insulin resistance.143 The antioxidant capacity of zinc is thought to underlie its valuable effects on IR.144 Two randomized controlled trials reported a reduction in fasting glucose and insulin in addition to other markers of IR in obese prepubescent children following zinc supplementation.145,146
Dosage The recommended dose of zinc is 20 mg/day.146 Precautions None reported at the recommended dose.
Chromium The trace element chromium is an important nutrient that helps prevent IR and dyslipidemia associated with obesity.129 Chromium also appears to have important effects on skeletal muscle IR.128 Chromium has been found to improve insulin sensitivity and increase glucose disposal in women with polycystic ovarian syndrome.130
Dosage The recommended dose of chromium is 200 to 1000 mcg/ day.130-132 Precautions Take chromium supplements half an hour before or 3 to 4 hours after thyroid or levothyroxine medications, as chromium may bind to these medications and reduce absorption.133
Magnesium Intracellular magnesium plays a vital role in regulating insulin action, insulin-mediated glucose uptake and vascular tone.134 Higher intakes of magnesium
Alpha lipoic acid Alpha lipoic acid (ALA) is a potent antioxidant that is considered important for the treatment of metabolic syndrome. The mechanisms by which ALA exerts its effects include protection against oxidative stress-induced IR, inhibition of hepatic gluconeogenesis, and increased peripheral glucose use.147 ALA may also exert modest reductions in plasma nonesterified fatty acid concentrations.148 When administered solely or in combination with the angiotensin receptor blocker irbesartan, ALA has been shown to improve endothelial function and reduce IL-6 and PAF-1 levels in subjects with metabolic syndrome.149
Dosage The recommended dose of ALA is 100 mg three times daily before each meal.149 Precautions None reported.
Coenzyme Q10 Coenzyme Q10 (CoQ10) is required for adenosine triphosphate (ATP) synthesis and is therefore important for the conversion of carbohydrates to energy.150 By enhancing the functioning of the mitochondrial enzyme glycerol-3-phosphate dehydrogenase, CoQ10 helps with glycemic control.128 A study by Singh et al.151 reported reductions in systolic and diastolic blood pressure, fasting and 2-hour plasma insulin, and triglycerides with the use of CoQ10 supplementation. Markers of oxidation, such as lipid peroxides, malondialdehyde, and diene conjugates, were also lowered by CoQ10, indicating a decrease in oxidative stress. Many patients with IR and metabolic syndrome are treated with statin drugs, and these medications have been found to lower plasma and tissue levels of CoQ10.152
Dosage The recommended dose of CoQ10 is 120 mg/day (or 60 mg twice daily).151 Precautions CoQ10 may decrease the anticoagulant effect of warfarin. Monitor clotting time regularly, particularly within the first 2 weeks of taking CoQ10.153
Acetyl-L-Carnitine The amino acid, carnitine, plays an important role in energy metabolism, largely through its effects on fatty acid oxidation. Carnitine deficiency has been associated with various conditions, including obesity and type 2 DM.154 When fatty acids are unable to enter the cell, triglycerides accumulate in the cytosol; an important contributor to the pathogenesis of IR. The administration of acetyl-L-carnitine to patients with type 2 DM and to healthy persons have been shown to improve insulin-mediated glucose disposal.155
Dosage The recommended dose of carnitine is 1 to 2 g/day between meals.156 Precautions None have been documented at the dose recommended.156
Omega-3 Fatty Acids Long term supplementation with omega-3 fatty acids has been shown to improve postprandial lipoprotein metabolism by decreasing triglycerides and increasing HDLcholesterol.2 Omega-3 fatty acids have also demonstrated improvements in endothelial function and arterial stiffness, with an accompanying reduction of the proinflammatory cytokine, IL-6.157
Dosage The recommended dose is 1 g/day of eicosapentaenoic acid and docosahexaenoic acid (EPA and DHA). For patients with elevated triglycerides, the dose is 2 to 4 g/day of EPA and DHA.157-159 Precautions None have been reported at the recommended dose.
Botanicals Ginseng (Panax ginseng) The herb Panax ginseng has numerous medicinal effects, including antiinflammatory and antioxidant properties, and has also been used in the treatment of type 2 DM. Ginseng is thought to control and prevent type 2 DM by increasing insulin sensitivity and enhancing insulin secretion.160 Another proposed mechanism of action lies in the herb’s ability to modulate glucose activity by increasing GLUT-4 transporter activity.161
Dosage The recommended dose is 100 to 200 mg/day (standardized to contain 4% ginsenosides).162,163 Precautions Ginseng may decrease the effectiveness of warfarin.164
Green Tea (Camellia sinensis) Green tea supplementation has been shown to improve whole blood glutathione and plasma antioxidant capacity and reduce plasma iron in adults with metabolic syndrome.165 Based on the research by Basu et al.,166 supplemental green tea in patients with metabolic syndrome is thought to reduce serum amyloid alpha, an independent cardiovascular disease risk factor. Green tea may also maintain normal body composition by stimulating thermogenesis and enhancing fat oxidation.167
Dosage Green tea extract (270 mg to 460 mg/day of epigallocatechin gallate).165-167 Precautions Green tea may decrease the effectiveness of warfarin.168 Do not combine with ephedrine or other stimulants.169
Milk Thistle (Silybum marianum) Milk thistle is considered an important herb in the treatment of hepatic disorders and also appears to play a
beneficial role in maintaining normal glucose and lipid metabolism. Liver dysfunction impairs the efficiency of postprandial hepatic glucose storage and is thought to trigger hyperinsulinemia due to reduced liver clearance of insulin.170 Phase III clinical trials have determined silymarin (the active component of milk thistle) to be the best medication for NAFLD due to its effects in lowering aminotransferase levels and reducing steatosis severity, liver ballooning, and fibrosis. Milk thistle has also been shown to act as an insulin sensitizer in studies of patients with NAFLD.171
Dosage Give 420 to 600 mg/day (standardized to contain 70%–80% silymarin).172,173 Precautions Exercise caution in patients taking drugs metabolized by cytochrome, the P-450 isoenzymes CYP3A4 and CYP2C9, because the silibinin content of milk thistle may inhibit these hepatic isoenzymes.174
Pharmaceuticals While lifestyle modification is the preferred approach to managing IR and metabolic syndrome, at times prescription drugs are necessary. The problem with such medications is that they do not correct underlying nutrient deficiencies. Medications often merely “treat” the results of the disease; that is, they reduce high serum lipid or glucose levels or high blood pressure but do not treat the overall patient. Although no FDA-approved prescription drugs exist for IR, many of the medications used for type 2 DM have studied as treatment of metabolic syndrome. Some of these medications may not specifically address IR or may have unhealthy side effects. For example, 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) lower serum CoQ10, and metformin reduces folic acid and vitamin B12 levels but may increase homocysteine levels. Statin administration is also associated with a dose-dependent increase in insulin resistance.175 Of importance is the fact that pharmaceutical drugs do not correct diet and lifestyle issues. Pharmaceuticals can be an appropriate complementary option when required. Following is a list of medications grouped according to their physiological action. There are a number of brands in each category, and many can be used in combination with each other. Even though these medications are usually used for type 2 DM, they are often prescribed for IR (although they may need to be prescribed “off-label”). It should be noted that medications approved for type 2 DM are the main medications being investigated for the treatment of NAFLD.58 Oral Medications Insulin Sensitizers. Biguanides (e.g., metformin) are the most commonly used front-line medications.
These drugs work by reducing glucose output from the liver (most likely by decreasing gluconeogenesis).176 Thiazolidinediones help improve body cell sensitivity to insulin by stimulating the nuclear receptor, peroxisome proliferator activated receptor (PPARgamma). These receptors are primarily found in fat cells and, to a lesser extent, in liver and skeletal muscle.176 Agents That Slow the Digestive/Absorptive Process. Alpha-glucosidase inhibitors help slow down the absorption of carbohydrate into the bloodstream following a meal, thereby reducing postprandial glucose peaks.177 Medications That Increase Insulin Production and Decrease Glucose Production. Dipeptidyl pepdiase-4 (DPP-4) inhibitors are a newer class of drugs that work by inhibiting the breakdown of incretin hormones glucagonlike peptide-1 and glucose dependent insulinotropic peptide. Increased levels of these hormones result in improved glucose-dependent insulin secretion, suppressed glucagon secretion, and reduced gastric emptying.178 Sodium-Glucose Transporter-2 (SGLT-2) Inhibitors. These medications work by a novel insulin-independent mechanism by blocking the reabsorption of glucose in the proximal convoluted tubules of the kidneys, thereby resulting in increased glucosuria and weight loss (due to loss of 300 to 400 kcal/day).179 Bile Acid Sequestrants. Colesevelam is a secondgeneration bile acid sequestrant and the only drug in this class that is approved for the treatment of hyperlipidemia and type 2 DM.180 Bile acid sequestrants work by binding bile acid in the intestinal lumen, thus impeding bile acid reabsorption in the terminal ileum and increasing fecal bile-acid output.181 A small study reported the efficacy of colesevelam in improving impaired fasting glucose levels.182
Surgery The most dramatic, but at times successful, option for the treatment of type 2 DM is bariatric surgery. While the majority of studies have focused on bariatric surgery for type 2 DM,183-189 there is research to support the use of this procedure in obese patients. In a nonrandomized, prospective, controlled study, bariatric surgery proved to be more efficient than usual care in the prevention of type 2 DM in obese persons. Subjects were divided into patients who underwent bariatric surgery (1658) and obese matched controls (1771). No participants had type 2 DM at baseline. After 15 years, type 2 DM developed in 392 participants in the control group compared with 110 in the bariatric surgery group, corresponding to incident rates of 28.4 cases per 1000 person-years and 6.8 cases per 1000 person-years, respectively (adjusted hazard ratio with bariatric surgery, 0.17; 95% CI, 0.13 to 0.21; P < 0.001).
PREVENTION PRESCRIPTION • M aintain a healthy body weight. People with an increase in visceral (truncal) fat are at higher risk. • Exercise of 30 minutes/day is recommended on most days of the week for patients with appropriate weight and 60 minutes/day on most days of the week for those needing to lose weight.
• M anage stress and increase the relaxation (parasympathetic) response. • Follow a low-glycemic load, Mediterranean-type diet. • Take a high quality multivitamin that includes minerals and B-group vitamins.
THERAPEUTIC REVIEW LABORATORY EVALUATION • 2-hour glucose and insulin tolerance test to measure glucose and insulin levels after a glucose load. • Serum lipid measurements (looking for increased triglyceride level, decrease in high-density lipoprotein cholesterol level, and normal or slightly increased low-density lipoprotein cholesterol level). • Fasting glucose higher than 100 mg/dL. • High-sensitivity C-reactive protein, a marker of inflammation, and gamma-glutamyltranspeptidase, a marker of liver toxicity.
• Note: The preceding recommendations highly outweigh those that follow for the treatment of IR and metabolic syndrome.
LIFESTYLE • Encourage an exercise routine that consists of modA erate intensity workouts and resistance training. • Encourage goals to achieve appropriate A weight. • Encourage the patient to stop using nicotine-containB ing products. NUTRITION • Low-carbohydrate, Mediterranean-type diet with a A focus on low-glycemic index foods. • High-fiber diet including soluble fibers, such as psylB lium, oats, and barley. • Decreased consumption of red meat and fried B foods. MIND-BODY THERAPIES • Encourage lifestyle choices to reduce stress and anxiety. Recommend a relaxation technique tailored to the individual.
SUPPLEMENTS • High-quality multivitamin with minerals and B-group vitamins. • Omega-3 fatty acids (eicosapentaenoic acid/ docosahexaenoic acid) 1 to 4 g/day to reduce inflammation, blood pressure, and triglyceride levels. • Chromium picolinate: 200 to 1000 mcg/day. • Vitamin C: 1000 to 2000 mg/day. 1
• Vitamin D: 300 to 2000 IU/day. • Alpha-lipoic acid: 100 to 300 mg/day. • Coenzyme Q10: 60 to 120 mg/day.
• H igh risk individuals may need to consider additional supplementation as outlined in the body of the text. BOTANICALS • American ginseng: 100 to 200 mg/day. • Milk thistle: 420 to 600 mg/day. PHARMACEUTICALS • Metformin: 500 to 2500 mg each morning or twice daily.
• Pioglitazone: 15 to 45 mg/day.
Key Web Resources The National Diabetes Information Clearinghouse (NDIC) provides information on insulin resistance and prediabetes
1. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR: Metabolic syndrome: definition, pathophysiology, and mechanisms, Am Heart J 149(1):33–45, 2005. 2. Jimenez-Gomez Y, Marin C, Peerez-Martinez P, et al.: A lowfat, high-complex carbohydrate diet supplemented with longchain (n-3) fatty acids alters the postprandial lipoprotein profile in patients with metabolic syndrome, J Nutr 140(9):1595–1601, 2010. 3. Alberti KG, Eckel RH, Grundy SM, et al.: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, Circulation 120(16):1640–1645, 2009. 4. Giacosa A, Rondanelli M: The right fiber for the right disease: an update on the psyllium seed husk and the metabolic syndrome, J Clin Gastroenterol 44(Suppl 1):S58–S60, 2010. 5. Lear SA, James PT, Ko GT, Kumanyika S: Appropriateness of waist circumference and waist-to-hip ratio cutoffs for different ethnic groups, Eur J Clin Nutr 64(1):42–61, 2010. 6. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation 112(17):2735–2752, 2005. 7. Penno G, Miccoli R, Pucci L, Del Prato S: The metabolic syndrome. Beyond the insulin resistance syndrome, Pharmacol Res 53(6):457–468, 2006. 8. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ: Prevalence of the metabolic syndrome in the United States, 2003-2012, JAMA 313(19):1973–1974, 2015. 9. Reaven G: Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease, Circulation 106(3):286–288, 2002. 10. Corona G, Monami M, Rastrelli G, et al.: Testosterone and metabolic syndrome: a Meta-Analysis Study, J Sex Med, 2010. 11. Griffith ML, Younk LM, Davis SN: Visceral adiposity, insulin resistance, and Type 2 diabetes, Am J Lifestyle Med 4(3):230–243, 2010. 12. DeFronzo RA: Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM, Diabetes 37(6):667–687, 1988. 13. Sesti G: Pathophysiology of insulin resistance, Best Pract Res Clin Endocrinol Metab 20(4):665–679, 2006. 14. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG: Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy, N Engl J Med 322(4):223–228, 1990. 15. Shulman GI: Cellular mechanisms of insulin resistance, J Clin Invest Title 106(2):171–176, 2000. 16. Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes, Diabetes Care 27(3):813–823, 2004. 17. Black PH: The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X, Brain Behav. Immun 17(5):350–364, 2003. 18. Petersen KF, Shulman GI: Etiology of insulin resistance, Am J Med 119(5 Suppl 1):S10–S16, 2006. 19. Sabanayagam C, Teppala S, Shankar A: Relationship between urinary bisphenol A levels and prediabetes among subjects free of diabetes, Acta Diabetol 50(4):625–631, 2013. 20. Brook RD, Cakmak S, Turner MC, et al.: Long-term fine particulate matter exposure and mortality from diabetes in Canada, Diabetes Care 36(10):3313–3320, 2013. 21. Thiering E, Cyrys J, Kratzsch J, et al.: Long-term exposure to traffic-related air pollution and insulin resistance in children: results from the GINIplus and LISAplus birth cohorts, Diabetologia 56(8):1696–1704, 2013. 22. Matsuzaki T, Sasaki K, Tanizaki Y, et al.: Insulin resistance is associated with the pathology of alzheimer disease: the Hisayama study, Neurology 75(9):764–770, 2010.
23. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A: Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study, Am Heart J 159(5):850–856, 2010. 24. Su LH, Chen TH: Association of androgenetic alopecia with metabolic syndrome in men: a community-based survey, Br J Dermatol 163(2):371–377, 2010. 25. Capasso I, Esposito E, Pentimalli F, et al.: Metabolic syndrome affects breast-cancer risk in postmenopausal women: National Cancer Institute of Naples experience, Cancer Biol Ther 10(12), 2010. 26. Pelucchi C, Negri E, Talamini R, et al.: Metabolic syndrome is associated with colorectal cancer in men, Eur J Cancer 46(10):1866–1872, 2010. 27. Bjorge T, Stocks T, Lukanova A, et al.: Metabolic syndrome and endometrial carcinoma, Am J Epidemiol 171(8):892–902, 2010. 28. Li D, Abbruzzese JL: New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts, Clin Cancer Res 16(17):4313–4318, 2010. 29. Gursoy A: Rising thyroid cancer incidence in the world might be related to insulin resistance, Med Hypotheses 74(1):35–36, 2010. 30. Mottillo S, Filion KB, Genest J, et al.: The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis, J Am Coll Cardiol 56(14):1113–1132, 2010. 31. Maloney EM, Boneva RS, Lin JM, Reeves WC: Chronic fatigue syndrome is associated with metabolic syndrome: results from a case-control study in Georgia, Metab Clin Exp 59(9):1351–1357, 2010. 32. Sun F, Tao Q, Zhan S: Metabolic syndrome and the development of chronic kidney disease among 118 924 non-diabetic Taiwanese in a retrospective cohort, Nephrology 15(1):84–92, 2010. 33. Komulainen P, Lakka TA, Kivipelto M, et al.: Metabolic syndrome and cognitive function: a population-based follow-up study in elderly women, Dement Geriatr Cogn Disord 23(1):29–34, 2007. 34. Kim JY, Mun HS, Lee BK, et al.: Impact of metabolic syndrome and its individual components on the presence and severity of angiographic coronary artery disease, Yonsei Med J 51(5):676–682, 2010. 35. Skilton MR, Moulin P, Terra JL, Bonnet F: Associations between anxiety, depression, and the metabolic syndrome, Biol Psychiatry 62(11):1251–1257, 2007. 36. Bansal TC, Guay AT, Jacobson J, Woods BO, Nesto RW: Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction, J Sex Med 2(1):96–103, 2005. 37. Chatzi L, Plana E, Pappas A, et al.: The metabolic syndrome in early pregnancy and risk of gestational diabetes mellitus, Diabetes Metab 35(6):490–494, 2009. 38. Yoo HG, Lee SI, Chae HJ, Park SJ, Lee YC, Yoo WH: Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis, Rheumatol Int, 2009. 39. Erdogan M, Canataroglu A, Ganidagli S, Kulaksizoglu M: Metabolic syndrome prevalance in subclinic and overt hypothyroid patients and the relation among metabolic syndrome parameters, J Endocrinol Invest, 2010. 40. West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H: Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994, Am J Kidney Dis 51(5):741–747, 2008. 41. Ahmed MH, Abu EO, Byrne CD: Non-alcoholic fatty liver disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes 4(3):129–137, 2010. 42. Zerati AE, Wolosker N, Ayzin Rosoky RM, Fernandes Saes G, Ragazzo L, Puech-Leao P: Prevalence of metabolic syndrome in patients with intermittent claudication and its correlation with the segment of arterial obstruction, Angiology 61(8):784–788, 2010. 43. Christophers E: Comorbidities in psoriasis, Clin Dermatol 25(6):529–534, 2007. 44. Jun J, Polotsky VY: Metabolic consequences of sleep-disordered breathing, ILAR J 50(3):289–306, 2009. 45. Magliano DJ, Loh VH, Harding JL, Botton J, Shaw JE: Persistent organic pollutants and diabetes: a review of the epidemiological evidence, Diabetes Metab 40(1):1–14, 2014. 46. Porta M: Persistent organic pollutants and the burden of diabetes, Lancet 368(9535):558–559, 2006.
47. Lee DH, Lee IK, Song K, et al.: A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002, Diabetes Care 29(7):1638–1644, 2006. 48. Lee DH, Lee IK, Porta M, Steffes M, Jacobs Jr DR: Relationship between serum concentrations of persistent organic pollutants and the prevalence of metabolic syndrome among non-diabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002, Diabetologia 50(9):1841–1851, 2007. 49. Kile ML, Christiani DC: Environmental arsenic exposure and diabetes, JAMA 300(7):845–846, 2008. 50. Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E: Arsenic exposure and prevalence of type 2 diabetes in US adults, JAMA 300(7):814–822, 2008. 51. Wang SL, Chang FH, Liou SH, Wang HJ, Li WF, Hsieh DP: Inorganic arsenic exposure and its relation to metabolic syndrome in an industrial area of Taiwan, Environ Int 33(6):805–811, 2007. 52. Druwe IL, Sollome JJ, Sanchez-Soria P, Hardwick RN, Camenisch TD, Vaillancourt RR: Arsenite activates NFkappaB through induction of C-reactive protein, Toxicol Appl Pharmacol 261(3):263–270, 2012. 53. Yilmaz Y: Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 36(9):815–823, 2012. 54. Duseja A, Singh SP, Saraswat VA, et al.: Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the indian national association for the study of the liver, endocrine society of india, indian college of cardiology and indian society of gastroenterology, J Clin Exp Hepatol 5(1):51–68, 2015. 55. Georgoulis M, Kontogianni MD, Margariti A, et al.: Associations between dietary intake and the presence of the metabolic syndrome in patients with non-alcoholic fatty liver disease, J Hum Nutr Diet, 2015. 56. Duvnjak M, Lerotic I, Barsic N, Tomasic V, Virovic Jukic L, Velagic V: Pathogenesis and management issues for non-alcoholic fatty liver disease, World J Gastroenterol 13(34):4539–4550, 2007. 57. Reference deleted in author review. 58. Polyzos SA, Kountouras J, Zavos C, Deretzi G: Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease, J Clin Gastroenterol 46(4):272–284, 2012. 59. Xiao J, Fai So K, Liong EC, Tipoe GL: Recent advances in the herbal treatment of non-alcoholic fatty liver disease, J Tradit Complement Med 3(2):88–94, 2013. 60. Reference deleted in author review. 61. Ong JP, Pitts A, Younossi ZM: Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease, J Hepatol 49(4):608–612, 2008. 62. Targher G, Arcaro G: Non-alcoholic fatty liver disease and increased risk of cardiovascular disease, Atherosclerosis 191(2): 235–240, 2007. 63. Summary of revisions for the 2010 Clinical Practice Recommendations, Diabetes Care 33(Suppl 1):S3, 2010. 64. Morstein M, C M, T S: Diagnosis and possible reversal of prediabetes, Nat Med 1(2):1–4, 2009. 65. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med 346(6):393–403, 2002. 66. Mann JI, Tipene-Leach DC, Pahau HL, et al.: Insulin resistance and impaired glucose metabolism in a predominantly maori community, Diabetes Res Clin Pract 72(1):68–74, 2006. 67. Schneider SH, Khachadurian AK, Amorosa LF, Clemow L, Ruderman NB: Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus, Diabetes Care 15(11):1800–1810, 1992. 68. Oh EG, Chu SH, Bang SY, et al.: Effects of a therapeutic lifestyle modification program on inflammatory chemokines and insulin resistance in subjects with metabolic syndrome, Biol Res Nurs, 2010. 69. Hegde SV, Adhikari P, Kotian S, Pinto VJ, D’Souza S, D’Souza V: Effect of 3-month yoga on oxidative stress in type 2 diabetes with or without complications: a controlled clinical trial, Diabetes Care 34(10):2208–2210, 2011.
70. Dvorak RV, DeNino WF, Ades PA, Poehlman ET: Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women, Diabetes 48(11):2210– 2214, 1999. 71. Hu FB, Li TY, Colditz GA, Willett WC, Manson JE: Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women, JAMA 289(14):1785– 1791, 2003. 72. Henry RR, Scheaffer L, Olefsky JM: Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus, J Clin Endocrinol 61(5):917–925, 1985. 73. Radzeviciene L, Ostrauskas R: Fast eating and the risk of type 2 diabetes mellitus: a case-control study, Clin Nutr 32(2):232–235, 2013. 74. Leong SL, Madden C, Gray A, Waters D, Horwath C: Faster self-reported speed of eating is related to higher body mass index in a nationwide survey of middle-aged women, J Am Diet Assoc 111(8):1192–1197, 2011. 75. Akbaraly TN, Singh-Manoux A, Tabak AG, et al.: Overall diet history and reversibility of the metabolic syndrome over 5 years: the Whitehall II prospective cohort study, Diabetes Care 33(11):2339–2341, 2010. 76. Esposito K, Marfella R, Ciotola M, et al.: Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial, JAMA 292(12):1440–1446, 2004. 77. Salas-Salvado J, Bullo M, Babio N, et al.: Reduction in the incidence of type 2-diabetes with the mediterranean diet: results of the PREDIMED-Reus Nutrition Intervention Randomized Trial, Diabetes Care, 2010. 78. Ludwig DS: The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease, JAMA 287(18):2414–2423, 2002. 79. Solomon TP, Haus JM, Kelly KR, et al.: A low-glycemic index diet combined with exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-dependent insulinotropic polypeptide responses in obese, prediabetic humans, Am J Clin Nutr 92(6):1359–1368, 2010. 80. Birlouez-Aragon I, Saavedra G, Tessier FJ, et al.: A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases, Am J Clin Nutr 91(5):1220–1226, 2010. 81. Stull AJ, Cash KC, Johnson WD, Champagne CM, Cefalu WT: Bioactives in blueberries improve insulin sensitivity in obese, insulin-resistant men and women, J Nutr 140(10):1764–1768, 2010. 82. Basu A, Du M, Leyva MJ, et al.: Blueberries decrease cardiovascular risk factors in obese men and women with metabolic syndrome, J Nutr 140(9):1582–1587, 2010. 83. Johnston CS, Kim CM, Buller AJ: Vinegar improves insulin sensitivity to a high-carbohydrate meal in subjects with insulin resistance or type 2 diabetes, Diabetes Care 27(1):281–282, 2004. 84. Liljeberg H, Bjorck I: Delayed gastric emptying rate may explain improved glycaemia in healthy subjects to a starchy meal with added vinegar, Eur J Clin Nutr 52(5):368–371, 1998. 85. Leeman M, Ostman E, Bjorck I: Vinegar dressing and cold storage of potatoes lowers postprandial glycaemic and insulinaemic responses in healthy subjects, Eur J Clin Nutr 59(11):1266–1271, 2005. 86. Davies MJ, Baer DJ, Judd JT, Brown ED, Campbell WS, Taylor PR: Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial, Jama 287(19): 2559–2562, 2002. 87. Clerc O, Nanchen D, Cornuz J, et al.: Alcohol drinking, the metabolic syndrome and diabetes in a population with high mean alcohol consumption, Diabet Med 27(11):1241–1249, 2010. 88. Foy CG, Bell RA, Farmer DF, Goff Jr DC, Wagenknecht LE: Smoking and incidence of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study, Diabetes Care 28(10):2501–2507, 2005. 89. Schulze MB, Manson JE, Ludwig DS, et al.: Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women, Jama 292(8):927–934, 2004.
References 90. Malik VS, Popkin BM, Bray GA, Despres JP, Willett WC, Hu FB: Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis, Diabetes Care 33(11): 2477–2483, 2010. 91. Gravenstein KS, et al.: Use of Artificial Sweeteners Linked to 2-Fold Increase in Diabetes: abstract P2-478. ENDO 2009, The Annual Meeting of the Endocrine Society, June 11, 2009. 2009. 92. Foreyt JP: The role of lifestyle modification in dysmetabolic syndrome management, Nestle Nutr Workshop Ser Clin Perform Programme 11:197–205, 2006. discussion 205-196. 93. Takeuchi T, Nakao M, Nomura K, et al.: Association of the metabolic syndrome with depression and anxiety in Japanese men: a 1-year cohort study, Diabetes Metab Res Rev 25(8):762–767, 2009. 94. Fletcher RH, Fairfield KM: Vitamins for chronic disease prevention in adults: clinical applications, JAMA 287(23):3127–3129, 2002. 95. Ford ES: Intake and circulating concentrations of antioxidants in metabolic syndrome, Curr Atheroscler Rep 8(6):448–452, 2006. 96. Schenk S, Saberi M, Olefsky JM: Insulin sensitivity: modulation by nutrients and inflammation, J Clin Invest Title 118(9):2992– 3002, 2008. 97. Inubushi T, Takasawa T, Tuboi Y, Watanabe N, Aki K, Katunuma N: Changes of glucose metabolism and skin-collagen neogenesis in vitamin B6 deficiency, BioFactors (Oxford, England) 23(2):59–67, 2005. 98. Kilicdag EB, Bagis T, Tarim E, et al.: Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial, Hum Reprod 20(6):1521–1528, 2005. 99. van der Griend R, Haas FJ, Biesma DH, Duran M, Meuwissen OJ, Banga JD: Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinaemia in patients with premature arterial disease and their relatives, Atherosclerosis 143(1):177–183, 1999. 100. Kahleova R, Palyzova D, Zvara K, et al.: Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins, Am J Hypertens 15(10 Pt 1):857–864, 2002. 101. Schneider MP, Schlaich MP, Harazny JM, et al.: Folic acid treatment normalizes NOS-dependence of vascular tone in the metabolic syndrome, Obesity 19(5):960–967, 2011. 102. Asemi Z, Karamali M, Esmaillzadeh A: Metabolic response to folate supplementation in overweight women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial, Mol Nutr Food Res 58(7):1465–1473, 2014. 103. Food and Nutrition Board, Institute of Medicine: Vitamin B12. Dietary Reference Intakes: thiamin, Riboflavin, Niacin, Vitamin B6, Vitamin B12, Pantothenic Acid, Biotin, and Choline, Washington D.C, 1998, National Academy Press. 104. Baltaci D, Kutlucan A, Turker Y, et al.: Association of vitamin B12 with obesity, overweight, insulin resistance and metabolic syndrome, and body fat composition; primary care-based study, Med Glas (Zenica) 10(2):203–210, 2013. 105. Setola E, Monti LD, Galluccio E, et al.: Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia, Eur J Endocrinol 151(4):483–489, 2004. 106. de Jager J, Kooy A, Lehert P, et al.: Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial, BMJ 340: c2181, 2010. 107. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials: Homocysteine Lowering Trialists’ Collaboration, BMJ 316(7135):894–898, 1998. 108. Ford ES, Mokdad AH, Giles WH, Brown DW: The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey, Diabetes 52(9):2346–2352, 2003. 109. Godala M, Materek-Kusmierkiewicz I, Moczulski D, et al.: [Estimation of plasma vitamin A, C and E levels in patients with metabolic syndrome], Pol Merkur Lekarski 36(215):320–323, 2014. 110. Johnston CS: Strategies for healthy weight loss: from vitamin C to the glycemic response, J Am Coll Nutr 24(3):158–165, 2005.
111. Pleiner J, Schaller G, Mittermayer F, Bayerle-Eder M, Roden M, Wolzt M: FFA-induced endothelial dysfunction can be corrected by vitamin C, J Clin Endocrinol 87(6):2913–2917, 2002. 112. Perticone F, Ceravolo R, Candigliota M, et al.: Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C, Diabetes 50(1):159–165, 2001. 113. Food and Nutrition Board: Institute of medicine, national academies, Dietary reference intakes (DRIs): tolerable upper intake levels (UL), Vitamins, 2004. 114. Fung GJ, Steffen LM, Zhou X, et al.: Vitamin D intake is inversely related to risk of developing metabolic syndrome in African American and white men and women over 20 y: the Coronary Artery Risk Development in Young Adults study, Am J Clin Nutr 96(1):24–29, 2012. 115. Zittermann A: Vitamin D and disease prevention with special reference to cardiovascular disease, Prog Biophys Mole Biol 92(1): 39–48, 2006. 116. Harkness LS, Bonny AE: Calcium and vitamin D status in the adolescent: key roles for bone, body weight, glucose tolerance, and estrogen biosynthesis, J Pediatr Adolesc Gynecol 18(5):305–311, 2005. 117. Boucher BJ, John WG, Noonan K: Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction, Am J Clin Nutr 80(6):1666, 2004. author reply 1666–1667. 118. Ford ES, Ajani UA, McGuire LC, Liu S: Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults, Diabetes Care 28(5):1228–1230, 2005. 119. Autier P, Gandini S: Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials, Arch Intern Med 167(16):1730–1737, 2007. 120. Gordina MA, Orlovskii VF: Effect of vitamin D correction on insulin resistance in patients with coronary heart disease and metabolic syndrome, Georgian Med News (227):32–36, 2014. 121. Holick MF: Vitamin D deficiency, N Engl J Med 357(3):266–281, 2007. 122. Tatro DS: Drug Interactions Facts, St. Louis, MO, 1999, Facts and Comparisons Inc. 123. Magosso E, Ansari MA, Gopalan Y, et al.: Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial, Nutr J 12(1):166, 2013. 124. Sanyal AJ, Mofrad PS, Contos MJ, et al.: A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol 2(12):1107–1115, 2004. 125. Polyzos SA, Kountouras J, Zafeiriadou E, et al.: Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease, J Renin Angiotensin Aldosterone Syst 12(4):498–503, 2011. 126. Scientific Committee on Food: Tolerable upper intake levels for vitamins and minerals, European Food Safety Authority, 2006. 127. McCarty MF: Up-regulation of PPARgamma coactivator-1alpha as a strategy for preventing and reversing insulin resistance and obesity, Med Hypotheses 64(2):399–407, 2005. 128. McCarty MF: Toward a wholly nutritional therapy for type 2 diabetes, Med Hypotheses 54(3):483–487, 2000. 129. Yang X, Li SY, Dong F, Ren J, Sreejayan N: Insulin-sensitizing and cholesterol-lowering effects of chromium (D-Phenylalanine)3, J Inorg Biochem 100(7):1187–1193, 2006. 130. Lydic ML, McNurlan M, Bembo S, Mitchell L, Komaroff E, Gelato M: Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome, Fertil Steril 86(1):243–246, 2006. 131. Anderson RA, Cheng N, Bryden NA, et al.: Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes, Diabetes 46(11):1786–1791, 1997. 132. Lee NA, Reasner CA: Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM, Diabetes Care 17(12):1449–1452, 1994. 133. John-Kalarickal J, Pearlman G, Carlson HE: New medications which decrease levothyroxine absorption, Thyroid 17(8):763–765, 2007. 134. Barbagallo M, Dominguez LJ: Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance, Arch Biochem Biophys, 2006.
135. He K, Liu K, Daviglus ML, et al.: Magnesium intake and incidence of metabolic syndrome among young adults, Circulation 113(13):1675–1682, 2006. 136. Rumawas ME, McKeown NM, Rogers G, Meigs JB, Wilson PW, Jacques PF: Magnesium intake is related to improved insulin homeostasis in the Framingham offspring cohort, J Am Coll Nutr 25(6):486–492, 2006. 137. Wang J, Persuitte G, Olendzki BC, et al.: Dietary magnesium intake improves insulin resistance among non-diabetic individuals with metabolic syndrome participating in a dietary trial, Nutrients 5(10):3910–3919, 2013. 138. Kim DJ, Xun P, Liu K, et al.: Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes, Diabetes Care, 2010. 139. Huerta MG, Roemmich JN, Kington ML, et al.: Magnesium deficiency is associated with insulin resistance in obese children, Diabetes Care 28(5):1175–1181, 2005. 140. Larsson SC, Wolk A: Magnesium intake and risk of type 2 diabetes: a meta-analysis, J Intern Med 262(2):208–214, 2007. 141. Rodriguez-Moran M, Guerrero-Romero F: Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial, Arch Med Res 45(5):388–393, 2014. 142. Peikert A, Wilimzig C, Kohne-Volland R: Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study, Cephalalgia 16(4):257–263, 1996. 143. Ahn BI, Kim MJ, Koo HS, Seo N, Joo NS, Kim YS: Serum zinc concentration is inversely associated with insulin resistance but not related with metabolic syndrome in nondiabetic Korean adults, Biol Trace Elem Res 160(2):169–175, 2014. 144. Taylor CG: Zinc, the pancreas, and diabetes: insights from rodent studies and future directions, Biometals 18(4):305–312, 2005. 145. Kelishadi R, Hashemipour M, Adeli K, et al.: Effect of zinc supplementation on markers of insulin resistance, oxidative stress, and inflammation among prepubescent children with metabolic syndrome, Metab Syndr Relat Disord, 2010. 146. Hashemipour M, Kelishadi R, Shapouri J, et al.: Effect of zinc supplementation on insulin resistance and components of the metabolic syndrome in prepubertal obese children, Hormones 8(4):279–285, 2009. 147. Konrad D: Utilization of the insulin-signaling network in the metabolic actions of alpha-lipoic acid-reduction or oxidation? Antioxid Redox Signal 7(7-8):1032–1039, 2005. 148. Manning PJ, Sutherland WH, Williams SM, et al.: The effect of lipoic acid and vitamin E therapies in individuals with the metabolic syndrome, Nutr Metab Cardiovasc Dis 23(6):543–549, 2013. 149. Sola S, Mir MQ, Cheema FA, et al.: Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study, Circulation 111(3):343–348, 2005. 150. Crane FL: Biochemical functions of coenzyme Q10, J Am Coll Nutr 20(6):591–598, 2001. 151. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS: Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease, J Hum Hypertens 13(3):203–208, 1999. 152. Nawarskas JJ: HMG-CoA reductase inhibitors and coenzyme Q10, Cardiol Rev 13(2):76–79, 2005. 153. Heck AM, DeWitt BA, Lukes AL: Potential interactions between alternative therapies and warfarin, Am J Health Syst Pharm 57(13): 1221-1227; 2000, quiz 1228–1230. 154. Reda E, D’Iddio S, Nicolai R, Benatti P, Calvani M: The carnitine system and body composition, Acta Diabetol 40(Suppl 1):S106– S113, 2003. 155. Mingrone G: Carnitine in type 2 diabetes, Ann N Y Acad Sci 1033:99–107, 2004. 156. Braverman ER: The Healing Nutrients Within, Laguan Beach, California, 2003, Basic Health Publications Inc. 157. Tousoulis D, Plastiras A, Siasos G, et al.: Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome, Atherosclerosis 232(1):10–16, 2014.
158. Vecka M, Dusejovska M, Stankova B, et al.: N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia, Neuro endocrinol Lett 33(Suppl 2):87–92, 2012. 159. Kris-Etherton PM, Harris WS, Appel LJ: Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association, Arterioscler Thromb Vasc Biol 23(2):151–152, 2003. 160. Liu TP, Liu IM, Cheng JT: Improvement of insulin resistance by panax ginseng in fructose-rich chow-fed rats, Hormone Metab Res 37(3):146–151, 2005. 161. Han KL, Jung MH, Sohn JH, Hwang JK: Ginsenoside 20S-protopanaxatriol (PPT) activates peroxisome proliferator-activated receptor gamma (PPARgamma) in 3T3-L1 adipocytes, Biol Pharm Bull 29(1):110–113, 2006. 162. Ginseng: many forms, many questions, not enough answers, Environmental Nutrition 21(6):8, 1998. 163. Sotaniemi EA, Haapakoski E, Rautio A: Ginseng therapy in noninsulin-dependent diabetic patients, Diabetes Care 18(10):1373– 1375, 1995. 164. Jiang X, Blair EY, McLachlan AJ: Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach, J Clin Pharmacol 46(11):1370–1378, 2006. 165. Basu A, Betts NM, Mulugeta A, Tong C, Newman E, Lyons TJ: Green tea supplementation increases glutathione and plasma antioxidant capacity in adults with the metabolic syndrome, Nutr Res 33(3):180–187, 2013. 166. Basu A, Du M, Sanchez K, et al.: Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome, Nutrition 27(2):206–213, 2011. 167. Dulloo AG, Duret C, Rohrer D, et al.: Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans, Am J Clin Nutr 70(6):1040–1045, 1999. 168. Taylor JR, Wilt VM: Probable antagonism of warfarin by green tea, Ann Pharmacother 33(4):426–428, 1999. 169. Haller CA, Benowitz NL: Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids, N Engl J Med 343(25):1833–1838, 2000. 170. McCarty MF: Potential utility of natural polyphenols for reversing fat-induced insulin resistance, Med Hypotheses 64(3):628–635, 2005. 171. Milosevic N, Milanovic M, Abenavoli L, Milic N: Phytotherapy and NAFLD–from goals and challenges to clinical practice, Rev Recent Clin Trials 9(3):195–203, 2014. 172. Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M: Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients, J Hepatol 26(4):871–879, 1997. 173. Somogyi A, Ecsedi GG, Blazovics A, Miskolczi K, Gergely P, Feher J: Short term treatment of type II hyperlipoproteinaemia with silymarin, Acta Med Hung 46(4):289–295, 1989. 174. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al.: Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes, Pharmacol Toxicol 86(6):250–256, 2000. 175. Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS: Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose, Int J Clin Pract 63(9):1308–1313, 2009. 176. Bullock S, Manias E, Galbraith A: Fundamentals of Pharmacology, ed 5, Frenchs Forest, NSW: Pearson Education Australia, 2007. 177. Scheen AJ, Esser N, Paquot N: Antidiabetic agents: potential anti-inflammatory activity beyond glucose control, Diabetes Metab, 2015. 178. Dokken B: Mechanisms of cardiovascular injury in type 2 diabetes and potential effects of dipeptidyl peptidase-4 inhibition, J Cardiovasc Nurs, 2015. 179. Dutta D, Kalra S: Sodium glucose transporter 2 (sglt2) inhibitors: current status in clinical practice, JPMA 64(10):1203–1206, 2014. 180. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P: Clinical Guidelines Committee of the American College of P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians, Ann Intern Med 156(3):218–231, 2012.
References 181. Charlton-Menys V, Durrington PN: Human cholesterol metabolism and therapeutic molecules, Exp Physiol 93(1):27–42, 2008. 182. Handelsman Y, Abby SL, Jin X, Donovan JM, Jones MR: Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes, Postgrad Med J 121(6):62–69, 2009. 183. Lukacova-Zib I, Gopalakrishnan G: Therapeutic options for the prevention of type 2 diabetes mellitus in the metabolic syndrome, Mt Sinai J Med 77(5):524–532, 2010. 184. Maleckas A, Venclauskas L, Wallenius V, Lonroth H, Fandriks L: Surgery in the treatment of type 2 diabetes mellitus, Scand J Surg 104(1):40–47, 2015. 185. Schauer PR, Kashyap SR, Wolski K, et al.: Bariatric surgery versus intensive medical therapy in obese patients with diabetes, N Engl J Med 366(17):1567–1576, 2012.
186. Kashyap SR, Bhatt DL, Wolski K, et al.: Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment, Diabetes Care 36(8):2175–2182, 2013. 187. Sjostrom L, Peltonen M, Jacobson P, et al.: Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications, JAMA 311(22):2297–2304, 2014. 188. Cho YM: A gut feeling to cure diabetes: potential mechanisms of diabetes remission after bariatric surgery, Diabetes Metab 38(6):406–415, 2014. 189. Brethauer SA, Aminian A, Romero-Talamas H, et al.: Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus, Ann Surg 258(4):628–636, 2013. discussion 636–627.